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Abstract Anorexia/cachexia is a common and currently
mostly untreatable complication of advanced cancer. It is
also a feature of a number of chronic diseases and can also
occur as part of the normal ageing process. Over recent
years, two different, but sometimes overlapping, processes
have been identified to mediate anorexia/cachexia: those
that act primarily on muscle reducing its mass and function,
and processes that decrease nutrition leading to loss of both
fat and muscle. In the case of at least some cancers, the latter
process is sometimes driven by marked overexpression of
macrophage inhibitory cytokine-1/growth differentiation
factor 15 (MIC-1/GDF15). MIC-1/GDF15 is a transforming
growth factor beta (TGF-β) family cytokine that is found in
the serum of all normal individuals at an average concen-
tration of about 0.6 ng/ml. Its increased expression in both
cancers and other diseases can result in 10–100-fold or more
elevation of its serum levels. In experimental animals, serum
MIC-1/GDF15 levels at the lower end of this range induce
anorexia by direct actions of the circulating cytokine on feed-
ing centres in the brain. Mice with tumours overexpressing
MIC-1/GDF15 display decreased food intake, loss of lean and
fat mass and cachexia. That this process also mediates anorex-
ia/cachexia in humans is suggested by the fact that there is a
direct correlation between the degree of serumMIC-1/GDF15
elevation and the amount of cancer-related weight loss, the
first such relationship demonstrated. Further, in experimental
animals, weight loss can be reversed by neutralisation of
tumour-produced MIC-1/GDF15 with a specific monoclonal
antibody, suggesting the possibility of effective therapy of
patients with the devastating complication of anorexia/
cachexia.
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1 Introduction
Worldwide, anorexia/cachexia is a common problem due to
inadequate nutrition or as a complication of a number of
chronic disease states and ageing. In the developing world,
inadequate nutrition causes cachexia [1] and eventually
death in many individuals. In the developed world, under-
nutrition and consequent cachexia is usually seen as part of
a disease process. Examples include coeliac disease, leading
to reduced nutrient absorption and anorexia nervosa, where
reduced intake leads to loss of fat and lean mass and often
cachexia [2, 3]. However in some diseases, most notably
advanced cancers, mediators produced directly or indirectly
by the tumour may cause anorexia and eventually cachexia.
Cancer anorexia/cachexia shortens life, causes great mor-
bidity, limits therapy and is responsible for about one quar-
ter of cancer deaths. The aetiological factors contributing to
the development of the anorexia/cachexia syndrome fall into
two broad and sometimes overlapping groups: factors that
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greatly decreased energy availability and/or those that
primarily lead to loss of muscle mass. Whilst the latter
has been most closely investigated, in more recent
times, it has become clear that anorexia, driving loss
of muscle mass, is also an important aetiological factor,
especially in cancer anorexia/cachexia. This review will
focus on the role of decreased energy intake in the
aetiology of this syndrome and in particular on the role
of the transforming growth factor beta (TGF-β) super-
family cytokine, macrophage inhibitory cytokine-1/growth
differentiation factor 15 (MIC-1/GDF15), in mediating this
process.
2 Overview of appetite regulation
Mammals have evolved a complex system to regulate
food intake and maintain appropriate energy stores,
dominantly in the form of fat and carbohydrates. Meal
size is controlled by short-term hormonal and neural
signals that are derived from the gut or pancreas, such
as ghrelin, which initiates meals [4], and cholecystoki-
nin, glucagon-like peptide-1, amylin and peptide YY [5,
6], which are satiety factors. Many of these act via the
area postrema (AP) and nucleus tractus solitarus in the
brainstem, as well as via the hypothalamus. Whilst
circulating mediators are excluded from the majority of
the CNS because of the specialised tight junctions of
the blood–brain barrier, they do access a limited number
of circumventricular organs that lack these tight junc-
tions. These circumventricular organs can be found in
the median eminence, which is immediately adjacent to
the arcuate nucleus (Arc) of the hypothalamus and the
AP. Thus, systemic hormones like insulin and leptin,
together with circulating nutrients, can act on these
areas to modulate multiple CNS pathways that then
converge on the hypothalamus to influence food intake
[7] and regulate long-term energy stores. For example,
energy deficiency activates powerful hypothalamic path-
ways involving increased expression and secretion of
neuropeptide Y (NPY) that increase appetite and de-
crease energy expenditure [8]. Energy deficit also leads
to decreased brain levels of alpha-melanocyte-
stimulating hormone (α-MSH, a cleavage product of
proopiomelanocortin (POMC)) and cocaine–amphet-
amine-related transcript, which oppose NPY actions [9].
Regulation of energy homeostasis is a complex and tight-
ly controlled process. However, it can also be modulated by
food availability and disease processes leading to either
obesity or severe weight loss and cachexia (Fig. 1). One
molecule that is both overexpressed in disease and capable
of modulating appetite is the TGF-β superfamily cytokine,
MIC-1/GDF15 [10].
3 MIC-1/GDF15 in appetite regulation and anorexia/
cachexia
MIC-1/GDF15 is a 25-kDa disulphide-linked dimeric stress
response protein [11] that is present in the circulation of all
individuals with a normal range of 150–1,150 pg/ml [12,
13]. Whilst its major site of synthesis is probably the liver, it
is also expressed in small amounts in the lungs, kidneys and
adipose tissue. In addition to this basal production, its ex-
pression is increased in most cells and tissues by inflamma-
tion, injury and malignancy [14]. Many cancers secrete large
amounts of MIC-1/GDF15 [15, 16], and biological, genetic
and in vitro data implicate it in cancer progression and
outcome [14, 16, 17]. For example, metastatic tumours of
the prostate, breast and colon markedly overexpress MIC-1/
GDF15, resulting in large increases in its serum levels,
sometimes to over 100,000 pg/ml [15]. Additionally, there
are diagnostically useful relationships between serum MIC-
1/GDF15 levels and many cancers, including those of the
colon [18], prostate gland [19–21] and pancreas [22, 23].
Further, MIC-1/GDF15 can modify tumour behaviour in
vivo and in vitro (reviewed in [14, 16, 17]). Our studies
also indicate that elevated serum MIC-1/GDF15, at least in
some cases, directly causes cancer anorexia/cachexia, as
outlined below.
3.1 Experimental data from animal models
We discovered that mice xenografted with tumours over-
expressing MIC-1/GDF15 became cachectic [10], with the
degree of weight loss proportional to the elevation of serum
MIC-1/GDF15 levels. Further, this weight loss could be
completely reversed by monoclonal antibodies to MIC-1/
GDF15 and reproduced by direct injection of recombinant
MIC-1/GDF15 subcutaneously. In these mice, the minimum
MIC-1/GDF15 serum concentrations associated with weight
loss was about 5 ng/ml, well within the serum level range
seen in patients with advanced cancer. Consistent with these
findings, transgenic mice overexpressing MIC-1/GDF15
weigh less than [10, 24, 25], and MIC-1/GDF15 germline
gene deleted mice weigh more, than their syngeneic controls
[26].
In cancer models, and when recombinant MIC-1/GDF15
was administered, weight loss was due to decreased food
intake rather than to altered metabolism, as indicated by
pair-feeding experiments involving restricting the food in-
take of a cohort of normal mice to that of syngeneic mice
treated with MIC-1/GDF15 [10]. Pair-feeding of normal
mice resulted in similar weight loss, with similar changes
in both fat and lean mass, as that produced by recombinant
MIC-1/GDF15 administration [10]. This experiment dem-
onstrates that similar changes in body weight and muscle
mass occur when the food intake of normal mice is reduced
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to that of MIC-1/GDF15 treated mice. Thus, the loss of
muscle mass in MIC-1/GDF15-treated mice can be fully
accounted for by reduced food intake, without incriminating
a direct action of MIC-1/GDF15 on muscle. Additionally,
overexpression of MIC-1/GDF15 in mice did not result in
any reduction in energy expenditure as determined by indi-
rect calorimetry [10], further highlighting the importance of
reduced food intake to the associated reduction in body
weight, adiposity and muscle mass. However, mice bearing
tumours overexpressing MIC-1/GDF15 also displayed a
number of other metabolic alterations; all of which were
consistent with reduced food intake. These included reduc-
tions in serum levels of glucose, free fatty acids and trigly-
cerides, leptin and IGF-1 [10]. Even in the face of reduced
leptin levels, reflecting reduced fat mass and associated
increased drive to eat, MIC-1/GDF15 was still able to re-
duce food intake. IGF-1 is an important regulator of lean
mass whose serum levels are reduced by MIC-1/GDF15
tumour expression as well as by energy restriction
[27–30]. IGF-1 is known to be low in cancer anorexia/
cachexia, and a reduction in serum IGF-1 levels with energy
deficit is likely to be one of the mechanisms mediating
reduction in muscle mass under these circumstances.
Consistent with its anorexigenic actions, systemic admin-
istration of MIC-1/GDF15 activated neurons in three brain
regions associated with appetite regulation: the AP, Arc and
the hypothalamic paraventricular nucleus [10], two of which
have a permeable capillary bed allowing systemic mediators
direct access to the otherwise tightly shielded brain. Further,
direct Arc injection of adeno-associated virus overexpress-
ing MIC-1/GDF15 also resulted in decreased food intake,
body weight and local neuronal activation, similar to the
effects of the systemically administered cytokine. To further
elucidate the mechanisms of action of MIC-1/GDF15, we
have studied its effects on the Arc in more detail. Systemic
injection of MIC-1/GDF15 decreased the Arc expression of
the major appetite stimulatory factor NPYand increased that
of the opposing anorexigenic factor, POMC. Both of these
changes could contribute to hypophagia resulting from
MIC-1/GDF15 administration. The major anorexigenic
cleavage product of POMC is α-MSH, the ligand for the
melanocortin 4 receptor, a major pathway also utilised by
leptin, one of the most important identified appetite-
suppressant molecules. Whilst the TGF-β superfamily re-
ceptor complex responsible for mediating the actions of
MIC-1/GDF15 has not been definitively identified, our
studies, subsequently supported by others, suggested that
MIC-1/GDF15 utilises the TGF-β RII receptor [31, 32] and
activates both ERK and STAT3 pathways.
3.2 Data from humans studies
There are strong experimental data in animals to indicate
that, when expressed in amounts comparable to those seen
in human malignancies and other chronic diseases, MIC-1/
GDF15 is able to suppress appetite and induce cachexia. To
obtain direct evidence for the relevance of MIC-1/GDF15 to
anorexia/cachexia in human disease, we have studied serum
from a number of patient cohorts. We measured serum levels
of MIC-1/GDF15 in a cohort of patients with advanced
prostate cancer, originally studied to determine the role of
TNF, IL-1 and IL6 in anorexia/cachexia [33]. In these
patients, the degree of weight loss over a 6-month period
was strongly correlated with prospectively collected serum
MIC-1/GDF15 levels [10]. There was no such correlation
with the other measured cytokines, although serum levels of
IL6, TNF-α and IL8 were higher in the cachectic subjects
[33]. Whilst these data have also been validated in a second
cohort of patients with advanced prostate cancer [20], no
relationship of MIC-1/GDF15 serum levels to nutritional
status could be identified in patients with oesophago-
gastric cancer, perhaps because of the overriding effect of
Fig. 1 Overview of systemic
physiological and disease-
related factors regulating appe-
tite and body mass
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gastrointestinal disruption [34]. However, in end-stage renal
failure, a condition in which MIC-1/GDF15 serum levels
can rise to up to 25 ng/ml, increasing serum levels of MIC-
1/GDF15 were also associated with reduced body mass
index (BMI) in 381 patients with end-stage renal failure on
dialysis [10]. Further, in a separate cohort of 98 patients
with end-stage renal failure, prior to dialysis, serum MIC-1/
GDF15 levels were able to identify patients with protein-
energy wasting [35]. Another condition in which serum
levels of MIC-1/GDF15 can rise substantially is chronic
heart failure [36]. In a paper identifying a role for MIC-1/
GDF15 as a marker of chronic heart failure severity, we can
also see that the group with the highest MIC-1/GDF15
levels have the lowest BMI [36]. Thus, whilst pathogenic
mechanisms have not been directly identified in humans,
across a number of diseases where serum levels of MIC-1/
GDF15 are elevated, there appears to be a consistent corre-
lation between increase in its serum levels and decrease in
markers of nutrition.
To the best of our knowledge, MIC-1/GDF15 is the only
putative causative agent for cancer anorexia/cachexia for which
it has been possible to identify a direct correlation between its
increasing serum levels and measures of body mass. In con-
junction with strong data in experimental animals indicating
anorexigenic actions for MIC-1/GDF15, the elevated serum
concentrations of MIC-1/GDF15 seen in certain human dis-
eases suggest that MIC-1/GDF15 is a cause of anorexia/ca-
chexia. It is unlikely however that it is the only cause. Human
studies using antibodies to MIC-1/GDF15, targeted to patients
with elevated MIC-1/GDF15 serum levels and early cachexia,
will be required to both unequivocally prove the role of this
molecule in human disease and determine whether targeting
this molecule is an effective therapeutic strategy.
3.3 Does MIC-1/GDF15 play a role in physiological appetite
regulation?
The relationship of elevated serum MIC-1/GDF15 levels to
food intake and bodymass raises the question as to whether its
levels, in the normal physiological range, play a role in regu-
lating food intake, body weight or metabolism. Currently,
there is little direct evidence available to allow any conclu-
sions to be drawn, and what little evidence available is diffi-
cult to interpret. However, MIC-1/GDF15 gene knockout
mice weigh more that syngeneic wild-type mice [26]. In
humans, defining any relationship between obesity or BMI
and serum MIC-1 concentrations is complicated by a number
of other potential modulators of its serum levels. Its serum
levels, within the normal range, are higher in obesity perhaps
because it is an adipokine or because of its production by
inflammatory cells that commonly reside within fat tissues
[37, 38]. Further, obesity is associated with insulin resistance,
which also raises MIC-1/GDF15 serum levels [37, 38].
4 Conclusion
The aetiology of anorexia/cachexia of cancer is multifactorial.
At the very least, it involves aetiological factors like depres-
sion, side effects of cancer therapy and mechanical disruption
to the gastrointestinal tract. It is also likely to involve media-
tors that are secreted by either tumour cells or other cells in the
tumour microenvironment. These may include anorexigenic
proteins like MIC-1/GDF15, cytokines whose primary action
is on the muscle such as myostatin and perhaps some pro-
inflammatory cytokines like IL6 and TNF-α. However, de-
spite a rapidly growing understanding of pathways capable of
causing anorexia/cachexia in experimental animals, there is
very limited evidence as to which pathways are triggered in
patients with disease processes associated with this complica-
tion. Ideally, whatever the putative mediator, one would ex-
pect to be able to demonstrate: (1) similar serum levels in
disease to those able to induce anorexia/cachexia in experi-
mental animals and (ii) a correlation, in patients, between its
serum levels and parameters of anorexia/cachexia. Ultimately,
however, the best test of the importance of the putative medi-
ator will be that its removal or inhibition in human disease will
reverse anorexia/cachexia.
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